Epigenomics AG
We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high medical need. Using blood as a liquid biopsy can improve patient access to cancer screening and thereby contribute to eradicate today’s deadliest cancer types such as colorectal, liver, and lung cancer. By leveraging our product pipeline and strong intellectual property, we aim to become a global leader in blood-based cancer detection.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Monitoring
- Market Focus:
- Globally (various continents)
- Year Founded:
- 1998
Our R&D mission
Initially, we started off as a pioneer in DNA methylation, exploiting this natural phenomenon with our proprietary technologies as a rich source of biomarkers. Today, we are developing and commercializing blood-based tests for the detection of cancer, using our proprietary DNA methylation biomarkers. Our high-performing, minimally-invasive tests are addressing high medical needs. Using blood as a liquid biopsy can improve patient access to cancer screening and detection and thereby contribute to eradicate today’s deadliest cancer types such as liver, lung and colorectal cancer. While we are dedicated to developing molecular diagnostic tests for cancer, we continuously improve our proprietary technology to maintain leadership in DNA methylation-based diagnostics.